Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.50 +0.11 (+0.45%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

June 13, 2025

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Ark Invest Continues To Offload Palantir, Loads Up On Beam Therapeutics, GitLab ↗

June 11, 2025

Via Benzinga

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

June 03, 2025

From Beam Therapeutics

Via GlobeNewswire

Analyst Expectations For Beam Therapeutics's Future ↗

February 27, 2025

Via Benzinga

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 29, 2025

From Beam Therapeutics

Via GlobeNewswire

BioMedNewsBreaks — Beam Therapeutics Inc. (NASDAQ: BEAM) to Present New Sickle Cell Data from BEACON Trial at EHA2025

May 23, 2025

Via Investor Brand Network

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 14, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 13, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 12, 2025

From Beam Therapeutics

Via GlobeNewswire

10 Analysts Assess Beam Therapeutics: What You Need To Know ↗

May 07, 2025

Via Benzinga

Why Beam Therapeutics Stock Tanked on Tuesday ↗

May 06, 2025

Via The Motley Fool

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 06, 2025

From Beam Therapeutics

Via GlobeNewswire

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗

April 21, 2025

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Via Investor's Business Daily

Topics Government

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗

April 21, 2025

Via Benzinga

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease ↗

April 07, 2025

Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND

Via Benzinga

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

April 05, 2025

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox ↗

April 04, 2025

Via Benzinga

Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' ↗

April 04, 2025

Via Benzinga

This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

March 28, 2025

Via Benzinga

Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock ↗

March 28, 2025

Via Benzinga

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

March 27, 2025

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen ↗

March 22, 2025

Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.

Via Benzinga

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity ↗

March 10, 2025

Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.

Via Benzinga

Beam Therapeutics Announces Pricing of Underwritten Offering

March 10, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

March 10, 2025

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Bold Move: 8 Straight Days Of Buying Beam Therapeutics As Stock Soars 14% ↗

March 04, 2025

Via Benzinga

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

February 25, 2025

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

February 24, 2025

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies ↗

February 22, 2025

Via Benzinga

Cathie Wood's Ark Invest Loads Up On Iridium, Twist Bioscience, Offloads Roku: Here Are Key Ark Trades This Friday ↗

February 15, 2025

Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.